In yesterday’s Wall Street session, Seres Therapeutics Inc. (NASDAQ:MCRB) shares traded at $4.69, up 6.11% from the previous session.
As of this writing, 7 analysts cover Seres Therapeutics Inc. (NASDAQ:MCRB). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $4.00, we find $11.00. Given the previous closing price of $4.42, this indicates a potential upside of 148.87 percent. MCRB stock price is now -5.85% away from the 50-day moving average and -18.09% away from the 200-day moving average. The market capitalization of the company currently stands at $565.29M.
There are 1 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $10.17 as their price target over the next twelve months.
In other news, Ege David S., insider sold 7,038 shares of the company’s stock on Apr 28. The stock was sold for $36,527 at an average price of $5.19. Upon completion of the transaction, the insider now directly owns 59,696 shares in the company, valued at $0.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 31, Ege David S. sold 5,012 shares of the business’s stock. A total of $39,745 was realized by selling the stock at an average price of $7.93. This leaves the insider owning 46,734 shares of the company worth $0.22 million. Insiders disposed of 12,050 shares of company stock worth roughly $56514.50000000001 over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MCRB stock. A new stake in Seres Therapeutics Inc. shares was purchased by AVORO CAPITAL ADVISORS LLC during the first quarter worth $6,074,000. HANDELSBANKEN FONDER AB invested $3,752,000 in shares of MCRB during the first quarter. In the first quarter, SIMPLIFY ASSET MANAGEMENT INC. acquired a new stake in Seres Therapeutics Inc. valued at approximately $2,582,000. AE WEALTH MANAGEMENT LLC acquired a new stake in MCRB for approximately $446,000. MACH-1 FINANCIAL GROUP, LLC purchased a new stake in MCRB valued at around $445,000 in the second quarter.
Friday morning saw Seres Therapeutics Inc. (NASDAQ: MCRB) opened at $4.5000. During the past 12 months, Seres Therapeutics Inc. has had a low of $3.91 and a high of $9.49. The fifty day moving average price for MCRB is $4.9736 and a two-hundred day moving average price translates $5.7144 for the stock.
The latest earnings results from Seres Therapeutics Inc. (NASDAQ: MCRB) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.57, missing analysts’ expectations of -$0.55 by -0.02. This compares to -$0.61 EPS in the same period last year. The company reported revenue of $-0.52 million for the quarter, compared to $1.49 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -134.96 percent. For the current quarter, analysts expect MCRB to generate $125.7M in revenue.
